
## **Supplemental Figures:**



**Figure S1. Indirect evidence for synthetic cross-links in** *Listeria monocytogenes* **and** *Escherichia coli*, **related to Figures 1 and 2.** (A-C) and (E-F) loss of fluorescence from monopeptide D-amino acid labeling followed by CuAAC. Wild-type *L. monocytogenes* EGDe (A-C) and *E. coli* K-12 (E-F) were incubated in the presence of the indicated D-amino acids, washed, and subjected to CuAAC with either azido- (A, E) or alkynyl-fluorophore (B, F) or to SPAAC with DBCO-CR110 (C). (D) *L. monocytogenes* peptidoglycan analysis. The *pbp5*::tn mutant was incubated or not with a mixture of alkyne-D-alanine (alkDA) and azido-D-lysine (azDlys), washed, and subjected to CuAAC with BTTP ligand. Peptidoglycan was extracted, digested with mutanolysin and lysozyme, and separated by ultra-performance liquid chromatography (UPLC). We were unable to detect differences between the chromatograms that were specific to both alkDA/azDlys and CuAAC treatments, presumably because of the pre-existing complexity of the Gram-positive peptidoglycan. Experiment was performed twice. (G) Loss of fluorescence from dipeptide D-amino acid labeling followed by CuAAC. CS802-2 *E. coli* were incubated in the presence of N-terminally-modified D-amino acid dipeptides azido-D-alanine-D-alanine (azDADA) or alkynyl- D-alanine-D-alanine (alkDADA), washed, and subjected to CuAAC with BTTP ligand and picolyl azide AF488.For (A-C) and (E-G), fluorescence was quantitated by flow cytometry and data are representative of 2-6 biological replicates performed in technical triplicate. MFI, mean fluorescence intensity. Error bars, +/- standard deviation of technical replicates.


A)

| D | ۱. |
|---|----|
| D |    |
|   |    |

D)


|              |                     | [H+M] +  |            |
|--------------|---------------------|----------|------------|
| lon          | Fragment lost       | Observed | Calculated |
| Parental Ion | -                   | 2090.878 | 2090.898   |
| 1            | GlcNAc              | 1887.817 | 1887.811   |
| 2            | GlcNAc, GlcNAc      | 1684.633 | 1684.724   |
| 3            | GlcNAc, GlcNAc,     | 1407.681 | 1407.608   |
| 2            | MurNAc              |          |            |
| 4            | GlcNAc, GlcNAc,     | 1059.423 | 1059.455   |
|              | MurNAc, MurNAc, Ala |          |            |
| -            | GlcNAc, GlcNAc,     | 930.38   | 930.412    |
| 5            | MurNAc, MurNAc,     |          |            |
|              | Ala, Glu            |          |            |
|              | GlcNAc, GlcNAc,     | 687.279  | 687.29     |
| 6            | MurNAc, MurNAc,     |          |            |
|              | Ala, Glu, DAP, Ala  |          |            |

|                   | -              |               |                |
|-------------------|----------------|---------------|----------------|
|                   | alkDa          | azDA          |                |
|                   | Dala/alkDA     | Dala/azDA     | Dala/azDA      |
|                   | -CuAAC         | -CuAAC        | +CuAAC         |
| % PG-Modification | 6.205 ± 0.81   | 10.615 ± 0.01 | 11.695 ± 1.08  |
| % Cross-linkage   | 53.8575 ± 1.15 | 46.84 ± 7.707 | 48.5175 ± 5.53 |



Observed mass [m/z]

Figure S2. Biochemical characterization of synthetic cross-links in E. coli, related to Figure 2. (A) MS/MS fragmentation of 5-5 triazole dimer. (B) Quantification of muropeptides from CS802-2 E. coli treated with Dala/alkDA or Dala/azDA and subjected or not to CuAAC. (C-D) Chemical structure and MS/MS profile of 5-5 triazole dimer. Data are from two biological replicates.



**Figure 2.** Ion detection (left) and MS profiles (right) for 5-5 triazole-linked trimer (A,B), trimer anh (C,D), and tetramer (E,F) from alkDA/azDA-labeled bacteria +/- CuAAC.




Figure S4. Impacts of D-amino acids and/or CuAAC on bacterial growth, viability and β-lactam susceptibility, related to Figure 3. (A) Experimental strategy for panels (B), (D-I), and Figure 3. ABX, antibiotics. (B) Growth of CS802-2 E. coli in the presence of the indicated D-amino acids pre-CuAAC. While Dala alone had no effect on growth, we observed a small but reproducible lag between 2 and 3 hours of incubation when CS802-2 E. coli was incubated at higher concentrations of alkDA and/or azDA. However, the growth rates stabilized and were similar between the strains after 4 to 5 hours of incubation. (C) pbp5::tn L. monocytogenes was incubated in the presence of the indicated D-amino acids, washed, and subjected or not to BTTP-liganded CuAAC. Serial dilutions were plated at the indicated time points and assessed the next day for colony-forming units (CFUs). (D-F) CS802-2 E. coli were labeled with the indicated combinations of D-amino acids overnight prior to BTTP-liganded CuAAC. Growth of Damino acid-treated bacteria post-CuAAC (E) or mock treatment (D). (F) Quantitation of lag time from (E). (G-H) CS802-2 E. coli were treated with indicated combinations of Damino acids, subjected to CuAAC, and immediately transferred to growth medium with (G) ampicillin or (H) carbenicillin. Serial dilutions were plated at the indicated time points and assessed for colony-forming units (CFUs). The experiment in (I) was performed similarly except that ampicillin was added *after* bacteria were out of lag phase (arrow), at OD<sub>600</sub> 0.5-0.6. Growth prior to ampicillin, solid lines; lysis in the presence of ampicillin, dashed lines. Error bars, +/- standard deviation. For (B), (D) and (I) data are representative of 2-5 biological replicates. For (C), (E-H) data are average of 3-12 biological replicates performed in triplicate. Statistical significance assessed by one- (F) or two-way (G-H) ANOVA with Tukey's multiple comparison test. \*, p<0.05; \*\*\*\*, p<0.0005; \*\*\*\*, p<0.0005. For (G-H), only the differences between strains treated with D-alanine and the combination of alkDa/azDA were significant.